Literature DB >> 10621945

Neuroprotective approaches in experimental models of beta-amyloid neurotoxicity: relevance to Alzheimer's disease.

T Harkany1, T Hortobágyi, M Sasvári, C Kónya, B Penke, P G Luiten, C Nyakas.   

Abstract

1. beta-Amyloid peptides (A beta s) accumulate abundantly in the Alzheimer's disease (AD) brain in areas subserving information acquisition and processing, and memory formation. A beta fragments are produced in a process of abnormal proteolytic cleavage of their precursor, the amyloid precursor protein (APP). While conflicting data exist in the literature on the roles of A beta s in the brain, and particularly in AD, recent studies have provided firm experimental evidence for the direct neurotoxic properties of A beta. 2. Sequence analysis of A beta s revealed a high degree of evolutionary conservation and inter-species homology of the A beta amino acid sequence. In contrast, synthetic A beta fragments, even if modified fluorescent or isotope-labeled derivatives, are pharmacological candidates for in vitro and in vivo modeling of their cellular actions. During the past decade, acute injection, prolonged mini-osmotic brain perfusion approaches or A beta infusions into the blood circulation were developed in order to investigate the effects of synthetic A beta s, whereas transgenic models provided insight into the distinct molecular steps of pathological APP cleavage. 3. The hippocampus, caudate putamen, amygdala and neocortex all formed primary targets of acute neurotoxicity screening, but functional consequences of A beta infusions were primarily demonstrated following either intracerebroventricular or basal forebrain (medial septum or magnocellular basal nucleus (MBN)) infusions of A beta fragments. 4. In vivo investigations confirmed that, while the active core of A beta is located within the beta(25-35) sequence, the flanking peptide regions influence not only the folding properties of the A beta fragments, but also their in vivo neurotoxic potentials. 5. It has recently been established that A beta administration deranges neuron-glia signaling, affects the glial glutamate uptake and thereby induces noxious glutamatergic stimulation of nerve cells. In fact, a critical role for N-methyl-D-aspartate (NMDA) receptors was postulated in the neurotoxic processes. Additionally, A beta s might become internalized, either after their selective binding to cell-surface receptors or after membrane association in consequence of their highly lipophilic nature, and induce free radical generation and subsequent oxidative injury. Ca(2+)-mediated neurotoxic events and generation of oxygen free radicals may indeed potentiate each other, or even converge to the same neurotoxic events, leading to cell death. 6. Neuroprotection against A beta toxicity was achieved by both pre- and post-treatment with NMDA receptor channel antagonists. Moreover, direct radical-scavengers, such as vitamin E or vitamin C, attenuated A beta toxicity with high efficacy. Interestingly, combined drug treatments did not necessarily result in additive enhanced neuroprotection. 7. Similarly to the blockade of NMDA receptors, the neurotoxic action of A beta s could be markedly decreased by pharmacological manipulation of voltage-dependent Ca(2+)-channels, serotonergic IA or adenosine A1 receptors, and by drugs eliciting membrane hyperpolarization or indirect blockade of Ca(2+)-mediated intracellular consequences of intracerebral A beta infusions. 8. A beta neurotoxicity might be dose-dependently modulated by trace metals. In spite of the fact that zinc (Zn) may act as a potent inhibitor of the NMDA receptor channel, high Zn doses accelerate A beta fibril formation, stabilize the beta-sheet conformation and thereby potentiate A beta neurotoxicity. Combined trace element supplementation with Se, Mn, or Mg, which prevails over the expression of detoxifying enzymes or counteracts intracellular elevations of Ca2+, may reduce the neurotoxic impact of A beta s. 9. Alterations in the regulatory functions of the hypothalamo-pituitary-adrenal axis may contribute significantly to neurodegenerative changes in the brain. Furthermore, AD patients exhibit substantially increased circadia

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10621945     DOI: 10.1016/s0278-5846(99)00058-5

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  11 in total

1.  Cyclooxygenase (COX)-1 activity precedes the COX-2 induction in Aβ-induced neuroinflammation.

Authors:  Leila Dargahi; Shiva Nasiraei-Moghadam; Azadeh Abdi; Leila Khalaj; Fatemeh Moradi; Abolhassan Ahmadiani
Journal:  J Mol Neurosci       Date:  2010-06-12       Impact factor: 3.444

2.  Effect of amyloid peptides on the increase in TrkA receptor expression induced by nicotine in vitro and in vivo.

Authors:  Xinyu D Li; Esperanza Arias; Ramamohana R Jonnala; Shyamala Mruthinti; Jerry J Buccafusco
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

3.  Neuroprotection by the synthetic neurosteroid enantiomers ent-PREGS and ent-DHEAS against Aβ₂₅₋₃₅ peptide-induced toxicity in vitro and in vivo in mice.

Authors:  Fadia El Bitar; Johann Meunier; Vanessa Villard; Marion Alméras; Kathiresan Krishnan; Douglas F Covey; Tangui Maurice; Yvette Akwa
Journal:  Psychopharmacology (Berl)       Date:  2014-01-31       Impact factor: 4.530

4.  Morphofunctional changes in neurons in the temporal cortex of the brain in relation to spatial memory in bulbectomized mice after treatment with mineral ascorbates.

Authors:  N V Bobkova; I V Nesteroval; R Dana; E Dana; V I Nesterov; Yu Aleksandrova; N I Medvinskaya; A N Samokhin
Journal:  Neurosci Behav Physiol       Date:  2004-09

5.  NMDA-mediated Ca(2+) influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer's disease mice.

Authors:  Ivan Goussakov; Megan B Miller; Grace E Stutzmann
Journal:  J Neurosci       Date:  2010-09-08       Impact factor: 6.167

6.  Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits.

Authors:  Hye Yun Kim; Dongkeun K Lee; Bo-Ryehn Chung; Hyunjin V Kim; YoungSoo Kim
Journal:  J Vis Exp       Date:  2016-03-16       Impact factor: 1.355

Review 7.  Intracellular A-beta amyloid, a sign for worse things to come?

Authors:  Valentina Echeverria; A Claudio Cuello
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.682

8.  An 5 GABAA Receptor Inverse Agonist, 5IA, Attenuates Amyloid Beta-Induced Neuronal Death in Mouse Hippocampal Cultures.

Authors:  Chitra Vinnakota; Karan Govindpani; Warren Perry Tate; Katie Peppercorn; Praju Vikas Anekal; Henry John Waldvogel; Richard Lewis Maxwell Faull; Andrea Kwakowsky
Journal:  Int J Mol Sci       Date:  2020-05-06       Impact factor: 5.923

Review 9.  Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease.

Authors:  Jelena Osmanovic Barilar; Ana Knezovic; Ana Babic Perhoc; Jan Homolak; Peter Riederer; Melita Salkovic-Petrisic
Journal:  J Neural Transm (Vienna)       Date:  2020-02-06       Impact factor: 3.575

Review 10.  Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases.

Authors:  P R Bharadwaj; K A Bates; T Porter; E Teimouri; G Perry; J W Steele; S Gandy; D Groth; R N Martins; Giuseppe Verdile
Journal:  Transl Psychiatry       Date:  2013-12-03       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.